James has over 20 years of experience within industry and academia, across the field of data engineering, AI and bioinformatics. He has also led various global teams, most of which had the aim of supporting biomedical R&D.

Before joining BenevolentAI, James worked as vice president of engineering at Logically.ai, as well as having held senior leadership roles at BenchSci and SciBite.

Dr Joerg Moeller, chief executive officer of BenevolentAI, stated: “On behalf of BenevolentAI, I want to thank Daniel Neil for his many achievements and dedication to the company over many years and wish him well for the future. We are excited to welcome James Malone to BenevolentAI as our new CTO. James’ extensive experience is aligned to the problems of drug discovery and development and AI approaches. Specifically, his experience in building technology to support R&D within biotech will help with the continuing development of the BenevolentAI PlatformTM, which is critical for us to deliver cutting-edge AI-driven drug discovery.”

Commenting on his new role, Dr James Malone added: “I’m excited to join the leadership team at BenevolentAI. I believe the combination of the Benevolent Platform, along with the company’s in-house scientific expertise, gives BenevolentAI strong foundations to continue to advance the use of AI in drug discovery and development to find life-changing treatments for patients.”